Literature DB >> 24855899

[Löfgren syndrome: a study of 80 cases].

Beatriz Tejera Segura1, Susana Holgado2, Lourdes Mateo2, Jose María Pego-Reigosa3, María Carnicero Iglesias4, Alejandro Olivé2.   

Abstract

BACKGROUND AND
OBJECTIVE: Löfgren's syndrome is characterized by hiliar adenopathies, erythema nodosum and arthritis. It is a benign variant of sarcoidosis, common in the Mediterranean area. To describe the clinical characteristics, treatment and outcome of a series of patients diagnosed with Löfgren's syndrome. PATIENTS AND METHODS: Retrospective design (1984-2013).
SETTING: Two university hospitals with a reference population of 1,015,000 inhabitants.
RESULTS: Eighty patients were diagnosed: 29 men and 51 women (mean age 42.3 years). Forty eight patients (60%) presented with the classical triad: hiliar adenopathies, erythema nodosum and arthritis; 18 (22%) with hiliar adenopathy and arthritis; 13 (16%) hiliar adenopathies and erythema nodosum. All showed abnormalities in the chest study. According to the radiological pattern, patients were classified in stage i-ii. Biopsy was performed in 39 patients and was diagnostic in 28. Treatment was based on non-steroidal anti-inflammatory drugs (54 patients, 67%) and corticosteroids (33 patients, 41%). Fourteen patients (17%) suffered a recurrence of the disease.
CONCLUSIONS: Löfgren's syndrome is a benign form of sarcoidosis with a well defined clinical pattern. Biopsy is usually not required. Recurrence is scarce. The disease has a good prognosis.
Copyright © 2013 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Eritema nodoso; Erythema nodosum; Löfgren's síndrome; Sarcoidosis; Síndrome de Löfgren

Mesh:

Substances:

Year:  2014        PMID: 24855899     DOI: 10.1016/j.medcli.2014.02.029

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  3 in total

Review 1.  [Musculoskeletal manifestations of sarcoidosis].

Authors:  P Korsten; G Chehab
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

Review 2.  Management of extrapulmonary sarcoidosis: challenges and solutions.

Authors:  Khalid Al-Kofahi; Peter Korsten; Christian Ascoli; Shanti Virupannavar; Mehdi Mirsaeidi; Ian Chang; Naim Qaqish; Lesley A Saketkoo; Robert P Baughman; Nadera J Sweiss
Journal:  Ther Clin Risk Manag       Date:  2016-11-07       Impact factor: 2.423

Review 3.  Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments.

Authors:  Geir Smedslund; Annie Martina Kotar; Till Uhlig
Journal:  Rheumatol Int       Date:  2022-08-09       Impact factor: 3.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.